Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs. Our mature and unique understanding of the science …

Agios has a proven track record of leveraging our expertise in cellular metabolism to develop new therapies and bring innovative medicines to patients in need. Building on our core capabilities, …

At Agios, building bonds and cultivating relationships are at the heart of our ability to create life-changing therapies for people with rare diseases. We are a biopharmaceutical company that …

At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life …

May 28, 2025 · Agios Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

At Agios, people living with rare diseases are at the center of everything we do and every decision we make. Their needs, concerns, input and collaboration are essential to fulfilling our mission: …

Agios is the pioneer in the science of pyruvate kinase (PK) activation. PK is an enzyme that plays an important role in regulating cell metabolism. It is responsible for the final step in glycolysis …

Find out what Agios is all about on this virtual tour of our space, led by sickle cell disease warrior DeMitrious Wyant. We’re proud to be a place where science meets heart, and meaningful …

Feb 13, 2025 · Agios is the pioneering leader in PK activation and is dedicated to developing and delivering transformative therapies for patients living with rare diseases. In the U.S. , Agios …

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation …